Tag Archives: Bristol-Myers Squib

April, 2018

May, 2016

  • 18 May

    FDA Grants Accelerated Approval to BMS’ Opdivo for Classical Hodgkin Lymphoma

    PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo®(nivolumab) for the treatment of patients with classical Hodgkin lymphoma (cHL) who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin.1 This accelerated approval is based on …

October, 2015

  • 29 October

    FDA Expands Approval of BMS’ Yervoy in Melanoma

    PRINCETON, N.J., Oct 28, 2015 (BUSINESS WIRE) — Bristol-Myers Squibb Company BMY, +0.60% today announced that the U.S. Food and Drug Administration (FDA) has approved Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm …